Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Saga Diagnostics AB has 4 pending office actions in Biotechnology & Pharmaceuticals. Each matter is associated with a distinct examiner and a distinct art unit, producing a one-to-one distribution across the reported prosecution activity.
JONES, CHRISTINE MICHELLE is the busiest examiner, with 1 pending matter. That workload is equal to the individual assignment shown for each examiner. A portfolio-wide review can help keep diagnostic terminology, written description positions, and amendment strategy consistent across the separate examination channels.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (50%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JONES, CHRISTINE MICHELLE | 1 | 0.0% | +0.0% |
| KALLAL, ROBERT JAMES | 1 | 59.4% | +31.2% |
| FONSECA LOPEZ, FRANCINI ALVARENGA | 1 | 28.6% | +30.0% |
| GREENE, CAROLYN LEE | 1 | 65.7% | +46.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18204703 | DETECTION OF TARGET NUCLEIC ACIDS | GREENE, CAROLYN LEE | 43d overdue |
| 18240453 | DETECTION OF VARIANT ESR1 SEQUENCES | JONES, CHRISTINE MICHELLE | — |
| 18240416 | MULTI-VECTOR DETECTION OF VARIANT SEQUENCES | KALLAL, ROBERT JAMES | — |
| 18240445 | STRUCTURAL VARIANT IDENTIFICATION | FONSECA LOPEZ, FRANCINI ALVARENGA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18204703 | DETECTION OF TARGET NUCLEIC ACIDS | GREENE, CAROLYN LEE | 43d overdue |
| 18240416 | MULTI-VECTOR DETECTION OF VARIANT SEQUENCES | KALLAL, ROBERT JAMES | — |
| 18240445 | STRUCTURAL VARIANT IDENTIFICATION | FONSECA LOPEZ, FRANCINI ALVARENGA | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1683 | 1 |
| 1685 | 1 |
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18240453 | DETECTION OF VARIANT ESR1 SEQUENCES | JONES, CHRISTINE MICHELLE | 1682 | §103§112DP | Non-Final OA | — | Pending | Aug 31, 2023 |
| 18240416 | MULTI-VECTOR DETECTION OF VARIANT SEQUENCES | KALLAL, ROBERT JAMES | 1683 | §101§103§112 | Non-Final OA | — | Pending | Aug 31, 2023 |
| 18240445 | STRUCTURAL VARIANT IDENTIFICATION | FONSECA LOPEZ, FRANCINI ALVARENGA | 1685 | §101§102§103§112 | Non-Final OA | — | Pending | Aug 31, 2023 |
| 18204703 | DETECTION OF TARGET NUCLEIC ACIDS | GREENE, CAROLYN LEE | 1681 | §102§103 | Final Rejection | 43d overdue | Pending | Jun 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSaga Diagnostics AB has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Christine Michelle Jones has the most, with 1 of Saga Diagnostics AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
